TY - JOUR
T1 - Efficacy and safety of pramipexole extended-release in clinical practice for Parkinson's disease
AU - Taguchi, Yoshiharu
AU - Takashima, Shutaro
AU - Dougu, Nobuhiro
AU - Nukui, Takamasa
AU - Konishi, Hirofumi
AU - Yoshida, Koji
AU - Hayashi, Tomohiro
AU - Yamamoto, Mamoru
AU - Tanaka, Kortaro
PY - 2014
Y1 - 2014
N2 - Objectives : To elucidate the efficacy of pramipexole extended-release (PPX-ER) formulation for the treatment of Parkinson's disease (PD) in clinical practice, we investigated PD patients who received regular outpatient treatment with PPX-ER at our department. Methods : Fifty-five patients in whom pramipexole immediate-release (PPX-IR) had been switched to PPX-ER (switch patients) and 37 patients who had been newly administered PPX-ER (newly-administered patients) at our department between July 2011 and May 2013 were included in the study. We retrospectively investigated the clinical characteristics and the efficacy and safety of treatment with PPX-ER based on patients' medical records. Results : Baseline characteristics of switch patients were as follows: age, 68.7 ± 8.3 years; female, 60.0%; duration of PD, 10.4 ± 5.8 years; Hoehn & Yahr stage, 3.0 ± 0.7; and the presence of wearing-off phenomenon, 58.2%. Improvement was observed in 21 out of 53 patients who were evaluated efficacy (39.6%). Side effects occurred in 20.0% of patients (11/55 patients), and 90.9% of patients (50/55 patients) continued PPX-ER throughout the study. In the newly-administered patients, baseline characteristics were as follows: age, 67.7 ± 8.9 years; female, 56.8%, duration of PD, 6.6 ± 5.4 years, Hoehn & Yahr stage, 2.4 ± 0.8; and the presence of wearing-off phenomenon, 32.4%. Sixteen out of 31 patients who were evaluated efficacy showed an improvement (51.6%). 10.8% of patients (4/37 patients) reported side effects, and 94.6% of patients (35/37 patients) continued PPX-ER Conclusions : Switching from PPX-IR to PPX-ER and newly administration of PPX-ER in PD patients are effective and well tolerated in clinical practice.
AB - Objectives : To elucidate the efficacy of pramipexole extended-release (PPX-ER) formulation for the treatment of Parkinson's disease (PD) in clinical practice, we investigated PD patients who received regular outpatient treatment with PPX-ER at our department. Methods : Fifty-five patients in whom pramipexole immediate-release (PPX-IR) had been switched to PPX-ER (switch patients) and 37 patients who had been newly administered PPX-ER (newly-administered patients) at our department between July 2011 and May 2013 were included in the study. We retrospectively investigated the clinical characteristics and the efficacy and safety of treatment with PPX-ER based on patients' medical records. Results : Baseline characteristics of switch patients were as follows: age, 68.7 ± 8.3 years; female, 60.0%; duration of PD, 10.4 ± 5.8 years; Hoehn & Yahr stage, 3.0 ± 0.7; and the presence of wearing-off phenomenon, 58.2%. Improvement was observed in 21 out of 53 patients who were evaluated efficacy (39.6%). Side effects occurred in 20.0% of patients (11/55 patients), and 90.9% of patients (50/55 patients) continued PPX-ER throughout the study. In the newly-administered patients, baseline characteristics were as follows: age, 67.7 ± 8.9 years; female, 56.8%, duration of PD, 6.6 ± 5.4 years, Hoehn & Yahr stage, 2.4 ± 0.8; and the presence of wearing-off phenomenon, 32.4%. Sixteen out of 31 patients who were evaluated efficacy showed an improvement (51.6%). 10.8% of patients (4/37 patients) reported side effects, and 94.6% of patients (35/37 patients) continued PPX-ER Conclusions : Switching from PPX-IR to PPX-ER and newly administration of PPX-ER in PD patients are effective and well tolerated in clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=84901297082&partnerID=8YFLogxK
M3 - 学術論文
AN - SCOPUS:84901297082
SN - 0289-8020
VL - 35
SP - 449
EP - 454
JO - Therapeutic Research
JF - Therapeutic Research
IS - 4
ER -